{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2024:SENWIXY3UTM5AIVNFNI3WOBJ7T","short_pith_number":"pith:SENWIXY3","canonical_record":{"source":{"id":"2411.13390","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.BM","submitted_at":"2024-11-20T15:27:12Z","cross_cats_sorted":[],"title_canon_sha256":"df7873ec936b17b9d07f4c714c9300f76df2f8656cf81eb53582a52137dedc93","abstract_canon_sha256":"75083327facd520d609cff83a48e7b3a59a71bb2d31a09d5a70593c90de489a3"},"schema_version":"1.0"},"canonical_sha256":"911b645f1ba4d9d022ad2b51bb3829fcefb5e29377a675b538027450ad48797a","source":{"kind":"arxiv","id":"2411.13390","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2411.13390","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"arxiv_version","alias_value":"2411.13390v1","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2411.13390","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_12","alias_value":"SENWIXY3UTM5","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_16","alias_value":"SENWIXY3UTM5AIVN","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_8","alias_value":"SENWIXY3","created_at":"2026-07-05T09:38:16Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2024:SENWIXY3UTM5AIVNFNI3WOBJ7T","target":"record","payload":{"canonical_record":{"source":{"id":"2411.13390","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.BM","submitted_at":"2024-11-20T15:27:12Z","cross_cats_sorted":[],"title_canon_sha256":"df7873ec936b17b9d07f4c714c9300f76df2f8656cf81eb53582a52137dedc93","abstract_canon_sha256":"75083327facd520d609cff83a48e7b3a59a71bb2d31a09d5a70593c90de489a3"},"schema_version":"1.0"},"canonical_sha256":"911b645f1ba4d9d022ad2b51bb3829fcefb5e29377a675b538027450ad48797a","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-07-05T09:38:16.272212Z","signature_b64":"rU4pF2sQ4C2+Yx32jwbDJ+//BHFjd+EzrbE1EW6FWRCt7n7XJBt0mcDMvVjGYLyBNtJn/hYNgQbffJUeHNiJAA==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"911b645f1ba4d9d022ad2b51bb3829fcefb5e29377a675b538027450ad48797a","last_reissued_at":"2026-07-05T09:38:16.271741Z","signature_status":"signed_v1","first_computed_at":"2026-07-05T09:38:16.271741Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"2411.13390","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T09:38:16Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"Pn716575u+bRVPZFLxSMrWORUGfwXyat6HBQaFU/IgtgtGmACa8QAm62kSVO97hbW3eLf03W0Pd3aZWApY16AQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-12T23:31:28.894711Z"},"content_sha256":"526abb8c9cee120a2d78c967b00108f6b1f629314c1e24f237e8674fca9f8651","schema_version":"1.0","event_id":"sha256:526abb8c9cee120a2d78c967b00108f6b1f629314c1e24f237e8674fca9f8651"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2024:SENWIXY3UTM5AIVNFNI3WOBJ7T","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Energy-based generative models for monoclonal antibodies","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"q-bio.BM","authors_text":"Aleksandra M. Walczak, Herv\\'e Minoux, Paul Pereira, Thierry Mora","submitted_at":"2024-11-20T15:27:12Z","abstract_excerpt":"Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite advances in biotechnology that accelerated the development of antibody drugs, the drug discovery process for this modality remains lengthy and costly, requiring multiple rounds of optimizations before a drug candidate can progress to preclinical and clinical trials. This multi-optimization problem involves increasing the affinity of the antibody to the target antigen while refinin"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2411.13390","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"integrity":{"clean":true,"summary":{"advisory":0,"critical":0,"by_detector":{},"informational":0},"endpoint":"/pith/2411.13390/integrity.json","findings":[],"available":true,"detectors_run":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938"},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-07-05T09:38:16Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"uuCDEK6U9Issm2Ged1OAUwwEbGRdV01d1G56IXZ5QdLlgRA0oBt181kDlsNS8DEfrys52qqMb5hqdBav3lCNCg==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-08-12T23:31:28.895254Z"},"content_sha256":"f751a4e6e1fdf84a233ef2b26b8f541287b7ed9195b03ef2b076c5a810e7a87f","schema_version":"1.0","event_id":"sha256:f751a4e6e1fdf84a233ef2b26b8f541287b7ed9195b03ef2b076c5a810e7a87f"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/bundle.json","state_url":"https://pith.science/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-08-12T23:31:28Z","links":{"resolver":"https://pith.science/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T","bundle":"https://pith.science/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/bundle.json","state":"https://pith.science/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/state.json","well_known_bundle":"https://pith.science/.well-known/pith/SENWIXY3UTM5AIVNFNI3WOBJ7T/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2024:SENWIXY3UTM5AIVNFNI3WOBJ7T","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"75083327facd520d609cff83a48e7b3a59a71bb2d31a09d5a70593c90de489a3","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.BM","submitted_at":"2024-11-20T15:27:12Z","title_canon_sha256":"df7873ec936b17b9d07f4c714c9300f76df2f8656cf81eb53582a52137dedc93"},"schema_version":"1.0","source":{"id":"2411.13390","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"2411.13390","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"arxiv_version","alias_value":"2411.13390v1","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.2411.13390","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_12","alias_value":"SENWIXY3UTM5","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_16","alias_value":"SENWIXY3UTM5AIVN","created_at":"2026-07-05T09:38:16Z"},{"alias_kind":"pith_short_8","alias_value":"SENWIXY3","created_at":"2026-07-05T09:38:16Z"}],"graph_snapshots":[{"event_id":"sha256:f751a4e6e1fdf84a233ef2b26b8f541287b7ed9195b03ef2b076c5a810e7a87f","target":"graph","created_at":"2026-07-05T09:38:16Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"integrity":{"available":true,"clean":true,"detectors_run":[],"endpoint":"/pith/2411.13390/integrity.json","findings":[],"snapshot_sha256":"c28c3603d3b5d939e8dc4c7e95fa8dfce3d595e45f758748cecf8e644a296938","summary":{"advisory":0,"by_detector":{},"critical":0,"informational":0}},"paper":{"abstract_excerpt":"Since the approval of the first antibody drug in 1986, a total of 162 antibodies have been approved for a wide range of therapeutic areas, including cancer, autoimmune, infectious, or cardiovascular diseases. Despite advances in biotechnology that accelerated the development of antibody drugs, the drug discovery process for this modality remains lengthy and costly, requiring multiple rounds of optimizations before a drug candidate can progress to preclinical and clinical trials. This multi-optimization problem involves increasing the affinity of the antibody to the target antigen while refinin","authors_text":"Aleksandra M. Walczak, Herv\\'e Minoux, Paul Pereira, Thierry Mora","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.BM","submitted_at":"2024-11-20T15:27:12Z","title":"Energy-based generative models for monoclonal antibodies"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"2411.13390","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:526abb8c9cee120a2d78c967b00108f6b1f629314c1e24f237e8674fca9f8651","target":"record","created_at":"2026-07-05T09:38:16Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"75083327facd520d609cff83a48e7b3a59a71bb2d31a09d5a70593c90de489a3","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"q-bio.BM","submitted_at":"2024-11-20T15:27:12Z","title_canon_sha256":"df7873ec936b17b9d07f4c714c9300f76df2f8656cf81eb53582a52137dedc93"},"schema_version":"1.0","source":{"id":"2411.13390","kind":"arxiv","version":1}},"canonical_sha256":"911b645f1ba4d9d022ad2b51bb3829fcefb5e29377a675b538027450ad48797a","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"911b645f1ba4d9d022ad2b51bb3829fcefb5e29377a675b538027450ad48797a","first_computed_at":"2026-07-05T09:38:16.271741Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-07-05T09:38:16.271741Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"rU4pF2sQ4C2+Yx32jwbDJ+//BHFjd+EzrbE1EW6FWRCt7n7XJBt0mcDMvVjGYLyBNtJn/hYNgQbffJUeHNiJAA==","signature_status":"signed_v1","signed_at":"2026-07-05T09:38:16.272212Z","signed_message":"canonical_sha256_bytes"},"source_id":"2411.13390","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:526abb8c9cee120a2d78c967b00108f6b1f629314c1e24f237e8674fca9f8651","sha256:f751a4e6e1fdf84a233ef2b26b8f541287b7ed9195b03ef2b076c5a810e7a87f"],"state_sha256":"3109b84daf4fa481a9e9c1614122942fca657a31036243b9c08da8717b53d517"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"EpWIH4TtwzwFauRkNcuQQLbVl/nNqZdyCyjQ6kFbGH/pg1eaY5b/AoCnaQ6A+AuY9LY6VU0UUecTLvOK1sCmDw==","signed_message":"bundle_sha256_bytes","signed_at":"2026-08-12T23:31:28.899918Z","bundle_sha256":"c320fc4126664b5c8e4b3d629583f68eb27ca3ed392881f19a8cbdcbededc28a"}}